The recent reductions in the US Food and Drug Administration’s workforce are poised to have a substantial impact on drug and biologic development programs. This LawFlash discusses strategies to optimize interactions with the...more
Earlier in the summer, the FDA issued a quartet of guidance documents setting forth the Agency’s plan for implementing requirements under the Drug Supply Chain Security Act (DSCSA). The DSCSA directs FDA to build an...more
9/21/2021
/ Coronavirus/COVID-19 ,
Drug Distribution ,
DSCSA ,
Food and Drug Administration (FDA) ,
Manufacturers ,
New Guidance ,
Pharmaceutical Industry ,
Pharmacies ,
Prescription Drugs ,
Supply Chain ,
Wholesale
The US Food and Drug Administration (FDA) has issued new guidance describing its current recommendations with respect to master protocols for the evaluation of drugs and biologics to treat or prevent COVID-19. ...more
6/1/2021
/ Biologics ,
Clinical Trials ,
Coronavirus/COVID-19 ,
Food & Drug Regulations ,
Food and Drug Administration (FDA) ,
Infectious Diseases ,
Life Sciences ,
New Guidance ,
Prescription Drugs ,
Regulatory Agenda ,
Regulatory Oversight ,
Standard of Care
In light of the hand sanitizer shortage during the coronavirus (COVID-19) emergency, many companies have been trying to find alternative sources of product, especially employers in healthcare and essential service sectors...more
The Agency improves the process for access to investigational drugs and biologics for patients who lack other options.
On June 2, the US Food and Drug Administration (FDA or the Agency) announced that it finalized three...more